Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / SST

SST

Basics

Aliases:
This biomarker is also known as:
  • Somatostatin-14,
  • somatostatin,
  • Growth hormone release-inhibiting factor,
  • Somatostatin-28,

Description…

The hormone somatostatin (SST) has active 14 aa and 28 aa forms that are produced by alternate cleavage of the single preproprotein encoded by this gene. Somatostatin is expressed throughout the body and inhibits the release of numerous secondary hormones by binding to high-affinity G-protein-coupled somatostatin receptors. This hormone is an important regulator of the endocrine system through its interactions with pituitary growth hormone, thyroid stimulating hormone, and most hormones of the gastrointestinal tract. Somatostatin also affects rates of neurotransmission in the central nervous system and proliferation of both normal and tumorigenic cells. The promoter of somatostatin, a primary inhibitor of gastrin-stimulated gastric acid secretion, is hypermethylated in 80% of human colon cancers. A synthetic analog of SST, known as octreotide or SMS 201-995, is available under the name Sandostatin (Novartis). It is used for the treatment of a variety of disorders including acromegaly and the symptomatic treatment of carcinoid tumors and vasoactive intestinal peptide tumors.

Attributes

QA State: Accepted
Type: Genomic
Short Name:
HGNC Name: SST

Organs

The following organs have data associated with this biomarker…

Esophagus

Attributes

Phase: Two
QA State: Accepted

Overview

Esophageal adenocarcinoma risk in Barrett's esophagus is increased 30- to 125- fold versus the general population. Among all Barrett's esophagus patients neoplastic progression occurs only once per 200 patient-years. Molecular markers (individual or in panel) would be useful to risk-stratify patients for more efficient surveillance endoscopy and to improve the early detection of progression.

Performance Comment

Promoter hypermethylation of SST can distinguish esophageal squamous cell carcinomas (ESCC) and esophageal adenocarcinomas (EAC) from normal esophagus. Studies investigating potential use of this protein as a biomarker are ongoing.

Supporting Study Data

The following studies/protocols provide evidence supporting SST indications for the Esophagus…

No supporting studies or protocols found.

Organ-Specific Protocols

No organ-specific protocols defined.

Organ-Specific Publications

No organ-specific publications defined.

Organ-Specific Resources

No organ-specific resources defined.

Studies

No associated studies or protocols found.

Biomuta

Mutation Statistics

Gene Name: SST
UniProt Accession #: P61278
Mutated Sites Count: 20
Associated Pubmed ID Count 6
CancerDO Count 16
Affected Protein Function Sites Count: 4

View in BioMuta